Last reviewed · How we verify
NCT06261021
Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
Phase 2 trial testing Ruxolitinib 1.5% cream in Discoid Lupus Erythematosus in 20 participants. Currently enrolling.
28 February 2026
Quick facts
| Lead sponsor | Innovaderm Research Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 19 April 2024 |
| Primary completion | 28 February 2026 |
| Estimated completion | 28 February 2026 |
| Sites | 2 locations across Canada |
Drugs / interventions tested
- Ruxolitinib 1.5% cream — full drug profile →
- Application without occlusion in Area 1
- Application under occlusion at night in Area 2
- Application under occlusion at night in Area 1
- Application without occlusion in Area 2
Conditions studied
- Discoid Lupus Erythematosus — all drugs for Discoid Lupus Erythematosus →
Sponsor
Innovaderm Research Inc. — full company profile →
Who can join
18 and older, any sex, with Discoid Lupus Erythematosus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-blind, intraindividual study to evaluate the efficacy of ruxolitinib 1.5 % cream in adult subjects with discoid lupus erythematosus.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06261021
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ruxolitinib 1.5% cream
Trials testing the same drug.
- NCT05247489 — A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo · Phase 2 · completed
- NCT03395340 — Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD) · Phase 2 · terminated
Other Innovaderm Research Inc. trials
Trials by the same sponsor.
- NCT06283550 — Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to · Phase 2 · completed
- NCT05835843 — Study to Assess the Reliability of PASI Scoring Using Digital-Based Images · completed
- NCT05844618 — Short-Term Efficacy of Triamcinolone Acetonide (Aristocort® C) in Subjects with Atopic Dermatitis · Phase 4 · completed
- NCT05602207 — Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab · Phase 4 · completed
- NCT03868098 — Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06261021 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Innovaderm Research Inc.
- Last refreshed: 24 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06261021.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing